Skip to main content

Advertisement

Fig. 3 | Clinical and Translational Allergy

Fig. 3

From: Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial

Fig. 3

Decrease in HDM-specific IgE levels (SE) compared with placebo 3 and 6 years after the start of treatment. D. pter—the mean change of IgE against D. pteronyssinus from baseline after 2 years of AIT or placebo, D. far—the mean change of IgE against D. farinae from baseline after 2 years of AIT or placebo, Derp1—the mean change of IgE against antigen D. pter 1 from baseline after 2 years of AIT or placebo, D. pter 2—the mean change of IgE against antigen D. pter 2 from baseline after 2 years of AIT or placebo. There were significant changes between the active and placebo group in all analysed parameters

Back to article page